ArticleJournal of orthopaedic translation2021
A novel tissue-engineered bone graft composed of silicon-substituted calcium phosphate, autogenous fine particulate bone powder and BMSCs promotes posterolateral spinal fusion in rabbits.
Article in Journal of orthopaedic translation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Measurement and evaluation of surgical models of spinal fusion in mice, rats, and rabbits.Animal models and experimental medicine · 2026Article
- Porous tantalum cage loaded with CGF promotes interbody fusion in a rat XLIF model.Scientific reports · 2025Article
- A Systematic Review of Metal Composite Bone Grafts in Preclinical Spinal Fusion Models.Biomimetics (Basel, Switzerland) · 2025Review
- Secreted Frizzled-Related Protein 2 Promotes Osteogenic Differentiation and Bone Regeneration in Perthes Disease When Targeted by miR-106a-5p.Journal of cellular and molecular medicine · 2025Article
- An innovative self-stabilised 3D-printed artificial vertebral body designed for clinical application and comparison with the conventional implants.Journal of orthopaedic translation · 2025Article
- Identification and function of periosteal skeletal stem cells in skeletal development, homeostasis, and disease.Journal of orthopaedic translation · 2025Review
- Evaluation of biological performance of 3D printed trabecular porous tantalum spine fusion cage in large animal models.Journal of orthopaedic translation · 2025Article
- Article
- Biodegradable Cements for Bone Regeneration.Journal of functional biomaterials · 2023Review
- Harvest of functional mesenchymal stem cells derived fromBiomaterials translational · 2023Article
- Effect of silicon or cerium doping on the anti-inflammatory activity of biphasic calcium phosphate scaffolds for bone regeneration.Progress in biomaterials · 2022Article
- Current strategies for enhancement of the bioactivity of artificial ligaments: A mini-review.Journal of orthopaedic translation · 2022Review
- An injectable pH neutral bioactive glass-based bone cement with suitable bone regeneration ability.Journal of orthopaedic translation · 2022Article
- Periosteum and development of the tissue-engineered periosteum for guided bone regeneration.Journal of orthopaedic translation · 2022Review
- Innovative biomaterials, drugs and technologies for musculoskeletal diseases.Journal of orthopaedic translation · 2022Article
- The "Three in One" Bone Repair Strategy for Osteoporotic Fractures.Frontiers in endocrinology · 2022Review
- A novel rat model of interbody fusion based on anterior lumbar corpectomy and fusion (ALCF).BMC musculoskeletal disorders · 2021Article
- Therapeutics for enhancement of spinal fusion: A mini review.Journal of orthopaedic translation · 2021Review
- [Local administration of parathyroid hormone and parathyroid hormone-related peptides for bone tissue engineering].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2021Review
- Medicine and models of degenerative orthopaedic disorders.Journal of orthopaedic translation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutogenous bone graft is the gold standard bone grafting substrate available in spinal fusion because of its osteoconductive, osteogenic, and osteoinductive properties. However, several shortcomings including bleeding, infection, chronic pain, and nerve injury are known to be associated with the procedure. Bone tissue engineering has emerged as an alternative therapeutic strategy for bone grafts. New materials have been developed and tested that can substitute for the autogenous bone grafts used in the spinal fusion. The purpose of this study is to evaluate the role of a novel tissue-engineered bone graft with silicon-substituted calcium phosphate (Si-CaP), autogenous fine particulate bone powder (AFPBP), and bone marrow mesenchymal stem cells (BMSCs) using a rabbit posterolateral lumbar fusion model based on bone tissue engineering principles. The application of this graft can represent a novel choice for autogenous bone to reduce the amount of autogenous bone and promote spinal fusion.
methodsBMSCs from New Zealand white rabbits were isolated and cultured in vitro. Then, BMSCs were marked by the cell tracker chloromethyl-benzamidodialkylcarbocyanine (CM-Dil). A total of 96 New Zealand White rabbits were randomly divided into four groups: (a) AFPBP, (b) Si-CaP, (c) Si-CaP/AFPBP, (d) Si-CaP/AFPBP/BMSCs.The rabbits underwent bilateral posterolateral spine arthrodesis of the L5-L6 intertransverse processes using different grafts. Spinal fusion and bone formation were evaluated at 4, 8, and 12 weeks after surgery by manual palpation, radiology, micro-computed tomography (micro-CT), histology, and scanning electronic microscopy (SEM).
resultsThe rate of fusion by manual palpation was higher in the Si-CaP/AFPBP/BMSCs group than the other groups at 8 weeks. The fusion rates in the Si-CaP/AFPBP/BMSCs and the AFPBP groups both reached 100%, which was higher than the Si-CaP/AFPBP group (62.5%) (P > 0.05) and Si-CaP group (37.5%) (P < 0.05) at 12 weeks. New bone formation was observed in all groups after implantation by radiology and micro-CT. The radiographic and CT scores increased in all groups from 4 to 12 weeks, indicating a time-dependent osteogenetic process. The Si-CaP/AFPBP/BMSCs group showed a larger amount of newly formed bone than the Si-CaP/AFPBP and Si-CaP groups at 12 weeks. Bone formation in the Si-CaP/AFPBP/BMSCs group was similar to the AFPBP group. Histology showed that new bone formation continued and increased along with the degradation and absorption of Si-CaP and AFPBP from 4 to 12 weeks in the Si-CaP, Si-CaP/AFPBP, and Si-CaP/AFPBP/BMSCs groups. At 4 weeks, a higher proportion of bone was detected in the AFPBP group (23.49%) compared with the Si-CaP/AFPBP/BMSCs group (14.66%, P < 0.05). In the Si-CaP/AFPBP/BMSCs group at 8 weeks, the area percentage of new bone formation was 28.56%, which was less than the AFPBP group (33.21%, P < 0.05). No difference in bone volume was observed between the Si-CaP/AFPBP/BMSCs group (44.39%) and AFPBP group (45.06%) at 12 weeks (P > 0.05). At 12 weeks, new trabecular were visible in the Si-CaP/AFPBP/BMSCs group by SEM. CM-Dil-positive cells were observed at all stages. Compared with histological images, BMSCs participate in various stages of osteogenesis by transforming into osteoblasts, chondrocytes, and osteocytes.
conclusionThis study demonstrated for the first time that Si-CaP/AFPBP/BMSCs is a novel tissue-engineered bone graft with excellent bioactivity, biocompatibility, and biodegradability. The graft could reduce the amount of autogenous bone and promote spinal fusion in a rabbit posterolateral lumbar fusion model, representing a novel alternative to autogenous bone. THE TRANSLATIONAL POTENTIAL OF THIS ARTICLE: The translational potential of this article lies in that this graft will be a novel spinal fusion graft with great potential for clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.